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Air, like food and water, is a necessity to the continuance 
of life. Unlike the latter two, lack of air is not tolerated long 
by man and indeed death is evident when it is lacking for greater 
than five minutes."'' 
The major challenge facing an infant during birth is changing 
2 
from one oxygen source to another. This changeover can only be 
accomplished if and when the lungs are structurally and functionally 
mature, so as to prevent collapse of expanded airways in inspiration 
and allow gaseous exchange. Asphyxia of the newborn and immaturity 
3 
account for 3-0 (1974) infant deaths per thousand live births, 
while the death rate from all causes accounts for 16.7 per thousand 
live births. Demonstrations have indicated that Respiratory Distress 
Syndrome (RDS), a symptom complex that arises secondary to deficiency 
of surfactant or a surface tension-lowering substance in the lung, 
is strongly related to prematurity, insofar as this is related to 
4-6 
shortened gestational age or immaturity. Respiratory Distress 
Syndrome or Hyaline Membrane Disease (HMD), the pathologic diagnosis, 
7 
account for an estimated twelve thousand neonatal deaths per year. 
2-7 
RDS/HMD is therefore, the leading cause of neonatal deaths, with 
congenital anomalies of the newborn and other diseases of early 
infancy being ranked second. 
This thesis highlights epidemiological risks and factors of 
the Respiratory Distress Syndrome, focuses on prenatal methods utilized 
in evaluation of fetal lung maturity, and attempts to disclose a new 

2 
simple method of assessing lung maturity of the fetus. 
The Normal Lung: 
In the normal lung development is in a glandular fashion at 
approximately twenty-eight days post conceptual age. The "canalicular 
g 
stage," or development of premature airways, lasts from the six¬ 
teenth week to approximately the twenty-fourth week. Thereafter, 
g 
the "alveolar stage," with development of alveolar ducts and 
bronchioles begins and continues until birth. 
The lung is fluid filled from the beginning of the "canalicular 
g 
phase," until birth. This fluid must be either expelled during 
delivery, with thoracic compression as it passes through the birth 
canal, or absorbed by capillaries and lymphatics, by movement of 
the fluid into the interstitial space, following initial inflation 
7 
of the lung after delivery. 
The alveolus is the portion most likely to be underdeveloped 
secondary to prematurity. During its development, there is a change 
in the appearance of the epithelial cells of its lining. These 
cells at approximately eighteen to twenty weeks are vacuolated and 
contain cytoplasmic inclusion bodies. The cells which line the 
alveolar ducts at this time are termed "alveolar epithelial Type II 
2 6 
cells." ’ Their presence has been noted to occur simultaneously 
with the occurrence of pulmonary surfactant in the extracts of lung 
tissues and indeed, production of cellular surfactant can be enhanced 
6) 18 




The greatest resistance to aeration or inflation of fetal 
lungs is produced by the surface tension of the lung liquid. 
Pulmonary surfactant in the lung liquid of the mature infant lowers 
the surface tension and thereby lowers the pressure needed to 
20 
inflate the smallest units of the lung or alveoli. This tension 
21 
lowering capacity is in keeping with the Law of Laplace, where 
pressure (P) is equal to tension (T) divided by the radius (r) 
multiplied by two, or P = 2 T/r. The pressure required to inflate 
the lung depends on the size of the radius, and on the presence or 
absence of surfactant, since this substance lowers the surface 
tension (T ). 
£ 
Since demonstrations suggested that fetal lung movements 
resulted in extrusion of endotracheal fluid containing pulmonary 
surfactant into amniotic fluid, many investigators began to try to 
unravel the composition of amniotic fluid and surfactant. The basic 
surfactant composition is a complex of many lipids, approximately 
eighty-five percent of which are phospholipids. Of these phospho¬ 
lipids, dipalmitoyl phosphatidylcholine (DPPC), or lecithin, make 
6 9 19 22 
up approximately seventy-five percent. ’ ’ ’ 
Not only was DPPC the principal component of surfactant, it 
also appeared to be the principal functioning component as well. 
By 1968, a detailed composition of human amniotic fluid had been 
reported. Nevertheless, it was not until 1971, that Gluck and 
coworkers suggested that the concentration of amniotic fluid 

4 
phospholipids might reflect formation of pulmonary surfactant and 
fetal lung maturity. There are five pathways of DPPC synthesis in 
the mammalian body. The cytidine diphosphate (CDP) pathway has 
been shown to be the major pathway of all lecithin synthesis. This 
synthesis has been shown to be active at approximately thirty-five 
weeks gestational age. There appears to be a smaller amount of 
lecithin synthesized by an alternative methylation pathway, at 
19 
approximately twenty-two to twenty-four weeks. This production 
19 
is of little significance. On the assumption that increasing 
amounts of amniotic fluid lecithin reflected increasing production 
of surfactant and hence maturation of the fetal lung, Gluck et al. 
suggested that at various ratios of lecithin to sphingomyelin in 
amniotic fluid, one could estimate lung maturation. Physiological 
control of pulmonary surfactant was investigated, and demonstrated 
that glucocorticoids tend to accelerate lung maturation. The 
hypothesis that RDS may therefore result from a deficiency in 
glucocorticoids has been examined. Indeed, infants who develop 
RDS tend to have lower cortisol levels than infants of comparable 
gestational ages. Investigators have also noted good correlation 
of cortisol levels with the L/S ratio. Some studies estimate that 
RDS will not develop at cortisol levels of greater than sixty 
24 
nanograms per milliliter. These lines have led to treatment of 
mothers with premature rupture of membranes or other high risk 
problems with glucocorticoids in an effort to increase pulmonic 
25 
maturation in the infants. Studies thus far have been encouraging, 
although further confirmation is necessary. 

5 
In summary, surfactant has been said to be the pulmonary 
surface-active material located in the alveolar lining layer. This 
anti-atelectasis factor provides a low and variable surface tension 
and serves the two fold function of decreasing the pressure needed 
to distend the lung, and maintains alveolar stability in a wide 
£ 
range of local volumes. 
Lung Pathology of Hyaline Membrane Disease: 
For infants with immature lungs each inhalation is as diffi¬ 
cult and demanding as the first because of the tendency, at exhalation, 
for the alveoli of the lungs to deflate completely and collapse 
producing atelectasis. This pathology known as Hyaline Membrane 
Disease, is manifested clinically as RDS. 
Criteria for diagnosis of Hyaline Membrane Disease differ 
among pathologists. Some pathologists require as criteria 
26 27 
atelectasis, membrane formation, or both. * Not surprisingly, 
investigators of the same case material may disagree in their 
28 
calculations of incidence. 
At autopsy, the lungs appear deep purplish red and are 
liverlike in consistency. Microscopically, the process is uniform 
throughout the lung with extensive atelectasis and engorgement of 
the interalveolar capillaries and lymphatics. Individual alveoli 
are rarely distinguished. Membranes are rarely present in those 
infants who live less than a few hours. Of those infants who live 
longer, a number of alveolar ducts and respiratory bronchioles are 

6 
lined with acidophilic homogeneous or granular membranes. Leukocytes 
are usually present in these infants, but are rarely found in those 
who live a short period of time. Epithelial necrosis of the 
respiratory bronchioles is an additional reaction that may suggest 
29 
injury. Amniotic fluid, intra-alveolar hemorrhage, pneumonia and 
interstitial emphysema are additional but inconsistent findings in 
the lungs of those infants who succumb after seven to ten days 
30 
secondary to other complications. 
Electro-microscopically, the membrane is composed of a 
cellular matrix of fibrin and cellular debris. The basement mem¬ 
brane of alveolar cells is disrupted and epithelial cells tend to 
31 32 
have a variable appearance. ’ The type II granular pneumocytes, 
where surfactant production is thought to take place, contain a 
large number of osmiophilic inclusion bodies. Since these inclusion 
bodies are thought to relate to pulmonary surfactant, many questions 
33 34 
arise as to their possible pathology. ’ 
Respiratory Distress Syndrome 
Epidemiology: 
Respiratory Distress Syndrome (RDS) is manifested in approxi¬ 
mately one percent of infants during the first days of the neonatal 
period. It continues to be the greatest killer of infants during 
that time interval. 

7 
Up until 1968, mortality statistics were based on estimated 
7 
figures. Farrell and Wood were the first to compile nationwide 
statistics to determine the extent of the disease. These results 
have shown an estimated national mortality rate of 28.8 per thousand 
premature births for 1968, that has risen to 35.9 for 1973. 
Mortality rates associated with HMD/RDS increased during the six 
year period from 2.36 per thousand live births, to 2.73 per thousand 
live births. On the basis of mortality rates, a trend toward an 
increased incidence of fatal HMD/RDS was established from 1968 to 
1973. This is attributed to greater diagnostic ability. Analysis 
of the mortality data during the 1968-1973 time period reveals a 
rather uniform seasonal distribution of RDS that clusters around 
the summer months, May through August, and shows, correspondingly, 
low points during the winter months, January through February. 
This occurrence is noteworthy, in terms of alerting clinicians to 
a greater mortality threat during particular time periods. Age at 
time of death from RDS decreased in an exponential fashion between 
the first and fourth days. Ninety-two percent of all deaths occurred 
by four days while ninety-six percent occurred by seven days of 
age. There appears to be an associated male predominance in 
fatality from RDS, at a ratio of 1.7/1. A greater number of white 
fatality, eighty-one percent, compared to eighteen percent for 
black fatality was noted. Black fatality was noted to be dispro¬ 
portionately high when one takes into account that they contribute 
only fifteen percent to the total birth rate. This higher rate is 




Respiratory Distress Syndrome as the clinical expression of 
an immature lung, leads to extremely labored breathing and perfusion 
of non-ventilated areas in the neonate. This pathology, evident 
35 
within two hours of birth, is clinically manifested m the newborn 
as cyanosis, chest wall and sternal retractions, tachypnea, 
37 
systemic hypotension, and expiratory grunting associated with 
whining and nasal flaring, that complete the picture of an infant 
39 
valiantly increasing its efforts to increase oxygenation. A 
characteristic chest film of a diffuse reticular granular pattern 
88 
with air bronchograms is usually evident. 
Physical examination can be helpful when signs of hypotension, 
fine bibasilar inspiratory rales, edema, ileus, and oliguria are 
present. 
Complicating the syndrome is a persistent Patent Ductus 
Arteriosus (PDA), leading to the possibility of development of 
severe congestive heart failure and pulmonary edema. This compli¬ 
cation is more than likely secondary to prematurity. Although PDA's 
usually close spontaneously after birth, it is estimated that the 
ductus remains patent in approximately ten to fifteen percent of 
3 
all premature infants. In these infants, the ductus usually closes 
spontaneously at approximately twelve weeks. In infants with RDS, 
this complication may greatly incapacitate the infant, requiring 
ligation of the ductus or closure by indomethacin. Since infants 
who suffered Premature Rupture of the Membranes (PROM) for greater 

9 
than seventy-two hours were noted to have a decreased persistence 
40 
of PDA's, it has been postulated that perhaps PROM should be 
tolerated for this period of time in premature infants to increase 
closure of the ductus. 
41-43 
Intracranial hemorrhage has been associated with HMD. 
This association may be due to tissue hypoxia prior to death, a 
decrease in clotting factors associated with hypoxia, or to elevated 
cerebral venous pressure secondary to grunting and increased 
respiratory effort. 
The exact diagnosis of HMD as a pathological diagnosis can 
only be verified at autopsy. There is nevertheless, a high corre¬ 
lation between the clinical findings, described as RDS, and the 
pathological findings of HMD.k,<^,^ 
Etiology: 
One of the most frequently cited associations with RDS is 
6 Q 22 v y 
prematurity/immaturity. ’ * Dunn, noted that of those neonatal 
deaths linked to RDS, eighty-one and one-half percent were among 
infants less than thirty-seven weeks gestation. Seventy-three and 
one-half percent were less than twenty-five hundred grams. An attempt 
was made to define prematurity and immaturity. The former encompassed 
low birth weight infants, of less than twenty-five hundred grams, 
whereas the latter comprised those infants of shortened gestational 
age who nevertheless might be heavier than average. On the basis 
of this separation, Dunn concluded that RDS was related to low birth 

10 
weight, only as this was related to immaturity, a conclusion that 
6 45 
is still undisputed. Usher and coworkers similarly correlated 
relationships of prematurity to the development of RDS. Unfor¬ 
tunately, much confusion has been perpetuated in the exact definition 
of prematurity, immaturity, and low birth weight. Authors con- 
46 
tinually use them interchangeably. Drillien and coworkers in 
fact define low birth weight and not prematurity, as less than 
twenty-five hundred grams and/or a gestational age of less than 
thirty-eight weeks. RDS appears in immature and/or low birth 
weight infants whose weights are low secondary to prematurity and 
49 
is a symptom of developmental immaturity. 
Immaturity/prematurity occur in approximately eight percent 
of all live births, to as high as fifteen percent in certain 
50 
hospitals. It seems inevitable with its high association to 
RDS, that investigators should turn to the many causes of prematurity. 
These are primarily environmental and maternal. 
Environmental factors have led to evidence that prematurity 
is greatest among poor, non-white, unmarried and older mothers with 
7 51 52 
inadequate prenatal care. * ’ It seems not at all surprising 
that low socio-economic factors, poor health, poor nutrition and 
obstetrical complications such as pre-eclampsia, infection and 
52 
ante-partum hemorrhage also lead to prematurity. Naeye and Blanc 
noted RDS to have an increased severity in white male infants, 
infants of Puerto Rican mothers who worked actively during their 
pregnancies, and among the offspring of the poor. 

11 
Of interest, is a possible genetic link to the development 
53 
of RDS. Lankernau and Opitz, noted an interesting relationship 
among premature first cousins of affected infants. Only the 
offspring of maternal aunts showed an increased incidence of RDS. 
This finding suggests the occurrence of a maternal dependent genetic 
factor predisposing the infants of certain mothers to developing 
RDS. RDS was increased in siblings by approximately twelve to 
nineteen percent. That incidence was increased to thirty to fifty 
percent, if these siblings were also of low birth weight or pre¬ 
mature. There was a relative absence of RDS among identical first 
born twins, while there appeared to be a greater occurrence among 
second born twins. This finding, correlates well with Verduzco 
54 
and coworkers finding that RDS occurs m twins and is predisposed 
by prematurity, with greater risk to twin B secondary to asphyxia. 
Maternal diseases add further to the risk of development of 
RDS. One important disease that has been implicated is maternal 
diabetes. 
Prior to the utilization of insulin, in 1921, most diabetic 
females were too ill to conceive, let alone bring to term the 
product of a conception. The precise etiology of this infertility 
is not clear. Of those mothers fortunate enough to conceive, 
during those times, a maternal mortality of twenty-five percent 
as well as a fifty percent infant mortality faced them. Diabetes 
was and still appears to be deleterious to a pregnancy in several 
ways. For instance, the incidence of pre-eclampsia and eclampsia 
55 
is increased approximately fourfold. A greater susceptibility 

12 
to infection and difficult delivery secondary to macrosomia of the 
infant are also evident. The fetus has a tendency to succumb before 
the onset of spontaneous labor and is, therefore, at greater risk 
for cesarean section and its potential complications. Postpartum 
hemorrhage is a very common occurrence in vaginal deliveries. 
Dystocia, birth trauma, and/or RDS and metabolic derangements that 
include hypoglycemia and hypocalcemia are common. The fetus of the 
diabetic mother, therefore, suffers a greater perinatal mortality 
and morbidity risk. Prognosis is, therefore, guarded, with mor¬ 
tality and morbidity related generally to maternal classification 
of diabetes. Cruz et al.^ noted that the only complication which 
added to the risk of development of RDS with any significance was 
insulin dependency. Although this study and others with similar 
conclusions attempt to show diabetes as a risk factor to the 
development of RDS, others, such as a large study at the Joslin 
57 
Clinic, indicate that only prematurity and not diabetes, nor any 
other severity of disease, influences the development of RDS. 
Class A or chemical diabetes is estimated to involve an infant 
mortality of 3.6 percent, while all other classes range from sixteen 
to twenty-three percent. Roberts and coworkers^ favored the finding 
58 59 
that RDS is associated v/ith certain classes of diabetes. ’ They 
hypothesized that insulin present in greater amounts in the fetus, 
secondary to maternal diabetes, may in fact antagonize cortisol by 
a blocking mechanism on its enzyme induction system capacity in the 
lung, leading to poor synthesis of surfactant and thereby predisposing 
these infants to the development of RDS. In keeping with this 
> 
13 
philosophy is a study by Smith, Giroud, and Avery,' where it is 
noted that, although cortisol enhanced lecithin synthesis and 
reduced cellular growth, addition of insulin abolished this stimu¬ 
lation effect. Therefore, hyperinsulinemia of the infant of the 
diabetic mother may interfere with the physiological process of 
glucocorticoid induced pulmonary maturity and may be a causal 
factor in the development of RDS in this group of infants. Although 
it would seem that a causal relationship might be established, 
there continues to be much debate on past and present evidence. 
Regardless of the disputes, it seems unfailingly clear that infants 
of diabetic mothers are at greater risk in developing RDS, be it 
secondary to insulin antagonism of cortisol or prematurity. 
Much controversy has centered around the incidence of 
development of RDS in the infant of the pre-eclamptic or eclamptic 
62 
mother. Pre-eclampsia, the development of hypertension with 
proteinuria and/or edema, usually occurs after the twentieth week 
of gestation and is induced by pregnancy. Eclampsia, commonly is 
the occurrence of convulsions, not secondary to any neurological 
disorder, but due to the underlying hypertension. Studies by 
Hendricks et al. and Lee and associates have noted the occurrence 
of the disorder to be associated with a higher incidence of pre¬ 
maturity, but a lower incidence of developing RDS. This lower 
incidence is most likely related to the glucocorticoid theory of 
maturation. Lee noted that those infants, of eclamptic mothers, 
less than thirty-three to thirty-six weeks or less than fifteen 
hundred grams had an incidence of RDS similar to uncomplicated 

14 
pregnancies of similar gestational age, inferring that lung 
maturation cannot be induced at very premature gestational ages. 
Premature rupture of membranes (PROM), classically defined 
as rupture of membranes prior to the onset of labor, has caused 
controversy regarding management of the expected fetus. Some 
authors advocate aggressive termination of the pregnancy to avoid 
the ever present danger of severe maternal and/or fetal infection. 
The possibility that the infant will then be capable of subsequent 
£>2 o 
normal development is then questioned. Numerous studies ^ have 
shown a tendency of increased pulmonic maturation associated with 
delayed birth following PROM. Unfortunately, much dispute has 
continued with regard to the actual amount of time necessary to 
64 
allow this maturation to occur. Chiswick and associates noted 
RDS to be decreased in infants born after forty-eight hours of 
PROM, when compared to those born after twenty-four to forty-eight 
hours. Others^’^ noted this decrease in RDS to occur at greater 
67 
than twenty-four hours after PROM, while Bauer et al. noted this 
49 
time period to be greater than sixteen hours. Lee et al. con¬ 
sidered the relationship to gestational age and noted a decrease 
in RDS only if infants weighed fifteen hundred to twenty-five 
hundred grams or were of a gestational age of thirty-three to 
68 
thirty-six weeks. Berkowitz et al. noted no decreased incidence 
of RDS in gestational ages between thirty-two to thirty-six weeks 
regardless of the length of PROM, but noted a significant decrease 
in RDS in infants less than thirty-two weeks who had suffered PROM 
for greater than sixteen hours. It may be concluded from these 

15 
and various other studies, that there is indeed an accelerating 
effect of PROM on the maturation of the fetal lung. Prolongation 
of PROM to sixteen to twenty-four hours may be of value to some 
infants in avoiding RDS, but other underlying factors must be 
involved in the maturation of the lung in other less fortunate 
infants. Clarification of management is therefore needed. 
Heroin and alcoholism have been investigated as to their 
effect on RDS. It has been noted^ ^ that infants of heroin 
addicted mothers did not suffer from an increased incidence of 
RDS, irrespective of gestational age. Infants of alcoholic mothers 
conversely not only suffered from a higher incidence of RDS but 
also of perinatal and postnatal growth deficiency, developmental 
delays and also congenital anomalies. 
Iatrogenic cesarean section is a potential complication 
71 
that increases the incidence of RDS. Studies by Hack et al. 
72 
and Goldenberg and associates have brought the implications to 
the foreground. These studies noted that fifteen to eighteen 
percent of infants develop RD.S secondary to obstetrical misjudgement 
of gestational age. This common dilemma, secondary to inadequate 
means of verifying clinically the gestational age of pregnancies 
at high risk, must be avoided. Fundal examination is obviously an 
inadequate measure of gestational age. New simple methods are, 
therefore, needed so as to safeguard the delivery of a term infant. 
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Complications of Amniocentesis: 
Prenatal analysis of amniotic fluid has become widespread 
following the discovery that amniotic fluid composition reflected 
fetal lung maturation and therefore, could be utilized to predict 
maturity. 
The majority of these techniques for analysis are based on 
the invasion of the uterus with withdrawal of amniotic fluid for 
analysis. Although this is a widely used obstetrical procedure for 
both diagnosis and therapy, most complications from the technique 
are associated with therapeutic indications. There are, nevertheless, 
real risks associated with amniocentesis for diagnostic purposes, 
such as evaluation of fetal maturity during late pregnancy. Of the 
complications reported, most have been associated with injury to 
the fetus, placenta, or umbilical cord. Occasionally, there have 
been those reported cases where the mother has been involved. Mid- 
trimester amniocentesis has been known to be relatively safe as 
compared to those performed at or close to term. It is these latter 
procedures that are generally utilized to assess fetal maturity, 
that warrant discussion. Numerous studies have noted risks that 
include, pneumothorax, pneumopericardium, splenic rupture or 
V 5 7£) 77 
laceration, ocular trauma, fetal exsanguination, intra and 
extraperitoneal major bleeding7^amniotic fluid embolism,^ 
8l 82 83 
chorioamnionitis, premature labor, abruptio placenta, ^ maternal 
rigors and pyrexia, fetal cardiac tamponade, J and, the most 
lethal, fetal and maternal death.^ These occurrences though rare 
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are real. In one study, spontaneous labor followed 9.8 percent 
of amniocentesis, with cesarean section for fetal distress necessary 
for seven percent. The most serious complication, fetal death, 
occurred in .41 percent of patients. Regardless of these compli¬ 
cations, amniocentesis for evaluation of fetal lung maturation has 
decreased the incidence of RDS in most institutions, and has 
eliminated the element of surprise postnatally for the obstetrician 
as well as for the pediatrician. Because of the potential compli¬ 
cations, it seems imperative that obstetricians carefully evaluate 
clinically gestational age in all patients and limit the utilization 
of this valuable technique for high risk patients. 
Methods of Prenatal Diagnosis: 
Prediction of the risk of development of RDS is important for 
often delivery can then be deferred or glucocorticoids administered 
in hopes of accelerating lung maturation. Following Avery and 
88 
Mead's observation that lungs from infants dying of HMD as well 
as from immature neonates were deficient in surfactant, more 
rational approaches to research were developed, especially by way 
of laboratory studies. 
Lecithin/Sphingomyelin: 
During the 1960's, the composition of surfactant was demon¬ 
strated. Composed almost totally of phospholipids, studies revealed 
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that these lipids increased with gestational age and that lecithin 
89 90 
was diminished in amniotic fluid of infants with RDS. ’ Using 
23 
this information, Gluck and coworkers reported the early prenatal 
prediction of fetal lung maturation, by evaluation of the lecithin/ 
sphingomyelin ratio (L/S). It has been confirmed that at a ratio 
of two, the likelihood that an infant will develop RDS, if delivery 
91 
is attempted, is minimal, and if such an infant does develop RDS, 
92 
morbidity is greatly reduced. Although confirmation has led to 
acceptance of its correlation with fetal lung maturity, it has been 
55 93 
noted by Gluck and coworkers and other researchers, that the 
L/S ratio in many high risk pregnancies does not yield as good a 
correlation as expected. These findings, suggest that perhaps 
biochemical maturation of the fetal lung may be either accelerated 
or delayed depending upon the maternal disease. Gluck and Kulovich 
noted two different means in the measurement of L/S ratios during 
gestation in various maternal diseases. Results indicated that 
pregnancies complicated by hypertension, eclampsia, renal disease, 
cardiovascular disease, diabetes mellitus of the D, E, F class, 
Sickle cell disease, and diseases of the placenta tended to have 
an accelerated maturation curve. The L/S ratio in these diseases 
would be at two at approximately thirty-two to thirty-three weeks 
as compared to normal maturation with an L/S of two at approximately 
thirty-five weeks. Other disease entities such as diabetes mellitus 
class A, B, C, chronic nonhypertensive glomerulonephritis and fetal 
diseases such as hydrops fetalis of Rh disease, and the smaller 
twin of non-parasitic monoclonal twins, tended to have delayed 
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maturation. The average fetal maturation of an L/S ratio of two 
was then approximately thirty-seven weeks gestation to as much as 
forty weeks. This last category is of great interest because these 
infants are at higher risk of development of RDS if delivered 
during a gestational age that would otherwise represent maturity. 
The L/S ratio is still the single best assessment of fetal 
94 95 
lung maturity, ’ since many problems in its determination have 
been elucidated. 
Centrifugation speed markedly affects the L/S ratio, and 
therefore may vary studies depending on preparation methods. It 
has been noted that the L/S ratio of mature fluid falls with 
97 
increasing gravitational force according to Cherayil et al. 
According to Gluck's method, sample preparation is done at 5,400 
rpm's for five to ten minutes and an L/S of two derived from this 
method is considered mature. If one lowers the gravitational force, 
interference with separation of lecithin and sphingomyelin spots 
may result on thin-layer chromatography and yield falsely high L/S 
ratios. It is not surprising that other studies evaluating L/S and 
RDS, have not provided similar results since changing Gluck's 
96 98 
original methodology may lead to error of prediction. ’ 
Other factors that have been implicated in accelerating or 
delaying L/S ratios are contamination of the fluid by blood or 
99 100 
meconium. Buhi and Spellacy, as well as Gluck and Kulkarni, 
noted that serum contained an L/S of approximately 1.31 to 1.46. 
Therefore, addition of serum to amniotic fluid decreases a high 
L/S ratio while it may increase a very low L/S ratio. Addition 
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of meconium decreased or increased the L/S ratio in a similar 
fashion. Because of these problems workers have investigated 
other means of determining fetal lung maturation or surfactant 
development. Gluck and coworkersnoted the correlation of 
levels of phosphatidylinositol and phosphatidylglycerol. The 
former was noted to increase during early gestation, the latter 
during late gestation paralleling lung maturity. These two 
parameters can add further to assessment of fetal lung maturation, 
and may lead to greater support of the mature L/S ratio report. 
A mature report at present does not guarantee that RDS will not 
occur since one to three percent of infants will develop RDS despite 
the report of maturity. The immature report, indicates that the 
risk of development of RDS is high and probable but not one hundred 
percent. 
Other Amniotic Fluid Methods: 
Total phospholipid concentration has been evaluated in order 
to devise a simple method of measuring fetal pulmonic maturity. 
102 103 
Nelson and Lawson, Schreyer and associates, as well as Singh 
et al.,^^ have noted a strong correlation of this method with the 
L/S ratio. These determinations unlike the L/S ratio are not 
dependent on a ratio or on the level of sphingomyelin. They are 
instead dependent on volume and have been shown to lack precision 





Clements and coworkers, introduced a fast, simple tech¬ 
nique, the foam test, dependent on pulmonary surfactant's ability 
to generate stable foam in the presence of ninety-five percent 
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ethanol. The foam test appears to :iave high predictive value 
when applied to non-contaminated amniotic fluid, for meconium and 
blood tend to mature the foam leading to false positive results. 
This rapid test has been applied postnatally as the gastric aspirate 
shake test for assessment of an infant's possibility of developing 
RDS,^^ and has become a further aid in the assessment of lung 
maturation. 
Recently, new literature on various methods of evaluation 
of amniotic fluids has arisen. 
Measurement of surface tension of amniotic fluid by Goldkrand 
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and coworkers ’ yields good correlation with the L/S ratio. 
A surface tension of less than fifty-six dynes per cm. at 120 micro- 
liters of extract and less than 46 dynes/cm., at 220 microliters 
of extract denotes pulmonic maturity or an L/S ratio of two. Blood 
and meconium contamination also appear to mature results. Their 
study revealed no false positive results, in comparison to the L/S 
ratio while 13.6 percent false negative results were attained. 
This method of measuring the surface tension lowering properties 
of amniotic fluid lipid extract appears to be a good direct method 
of assessment of fetal lung maturity. Since this method correlates 
well with the L/S ratio yet is quicker, and more direct, it seems 
logical that future advances in this method may add to its precision 
and to our clinical knowledge of fetal lung maturation. 
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A similar analysis derived from the above method is the 
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lipid globule technique. This method based on surface tension, 
involves the utilization of surface tension lowering properties 
of amniotic fluid lipid extract and its ability to form a globule 
when the surface tension reaches 36.9 dynes per centimeter. Since 
the amount of extract required to create a globule varies dependent 
on the degree of fetal maturity, the volume required can be used 
to differentiate pulmonic maturity. The RDS predictive value was 
one hundred percent but resulted in nine out of seventy or a twelve 
percent false negative value. Thus far the predictive value of 
surface tension analysis seems encouraging, but tends to have false 
negative results that may create difficult decision making problems 
for the obstetrician. Perhaps, with further analysis, advances 
will be made to avoid this pitfall. 
Optical density analysis at 650mm of amniotic fluid intro¬ 
duced by Sbarra et al.,^^ provides a very simple measure that is 
thought to correlate with the L/S ratio. An optical density of 
0.15 or greater, correlates one hundred percent with an L/S ratio 
of two or greater, below 0.15 correlates ninety-four percent with 
an L/S ratio of less than two but resulted in a value of six percent 
false negatives. In this small and first study, more data is 
needed to evaluate further the findings suggested. 
The L/S ratio continues to command the obstetrical scene at 
the moment; however many problems that have been discussed have 




Analysis of other components of anniotic fluid such as fetal 
cells,creatinine,as well as hormonal levels of estrogens^^ 
and thyroid'*'^ have not yielded information that can precisely 
aid the clinician in a decision making position. However, many 
have added to the understanding of lung development such as the 
relationship between cortisol and fetal maturation. However, 
further investigation is needed in all areas to establish precise 
evaluation and understanding both clinically and physiologically. 
A New Method of Analysis of Fetal Lung Maturity: 
The foregoing discussion of RDS, as well as review of pre¬ 
natal methods of analysis, show advances in medicine that reflect 
much thought and time. These thoughts are a fitting introduction 
to the analysis of a new method for assessment of fetal lung 
maturity, which takes into account the whole surfactant composition 
and is independent of the lipid level of amniotic fluid. 
The following study is based on a specially designed instru- 
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ment, the "Elscint Fetal Lung Maturity Analyzer." This instrument 
evaluates surfactant composition based on fluorescent polarization 
(FP). The analysis of the recorded signal, FP, is a function 






The fluorescent polarization technique utilizes a hydrocarbon 
chemical probe, 1,6-diphenyl 1,3,5,-hexatiene (DPH), and is a good 
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measure of the microviscosity of cell membranes and liposomes. 
The values obtained are determined by measuring the amount of 
rotation of the DPH dye probe in a sample of amniotic fluid. This 
rotation is dependent on the microviscosity of the hydrocarbon 
region of the lipids. It has been shown that polarization of DPH, 
decreases as the L/S ratio increases. The FP value is a measure of 
the intrinsic microviscosity of the lipids. Under experimental con¬ 
ditions, the value of a DPH labelled specimen can extend between 







Ijj = fluorescent intensities directed through an 
analyzer with the direction of polarization 
parallel to the direction of polarization of 
the excited light. 
Ij = fluorescent intensities directed through an 
analyzer with the direction of polarization 
perpendicular to the direction of polarization 




A specially designed instrument is utilized whereby light 
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is polarized by a Glan-Thompson polarizer and excites the DPH 
probe dissolved in the dispersion of amniotic fluid and phosphate 
buffered saline (PBS). Microviscosity is dependent on temperature. 
Therefore, the cuvette containing the amniotic fluid to be sampled, 
is placed in a thermoelectrically temperature stabilized compartment 
with a temperature of twenty-five degrees centigrade. The emitted 
light from the probe is polarized as a function of the microviscosity. 
This polarization is detected by measuring two perpendicular channels 
that tend to measure the intensity of light. This measurement is 
amplified, balanced, and fed to a calculating unit. The calculated 
depolarization value is digitalized and displayed on the front 
panel of the instrument. This value, FP, is related to lung maturation, 
by correlation with the L/S ratio and gestational age. 
C. Amniotic Fluid Samples: 
Samples of amniotic fluid were made available for this study 
from patients who underwent amniocentesis for prenatal evaluation 
at the Perinatal Unit of Yale New Haven Hospital, during 11/76 
through 2/78. Each sample was labelled with type of disease, and 
gestational age. Almost all samples were sent for L/S ratios except 
many of those from Rh patients. Samples were examined immediately 
or frozen to be done later. Long term freezing and thawing at any 
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time up to three months did not seem to affect the FP value in any 
uniform way. 
D. Materials: 
1. DPR Fluorescent Probe: 
Sealed ampules of fluorescent molecular probe EF-101 were 
obtained from Elscint LTD. These were stored at room temperature 
in aluminum foil. 
2. Dulbecco's Phosphate Buffered Saline (PBS): 
Each of the following: 
Nacl 8.5 gm./liter 
NaH2P0^ 0.1 gm./liter 
Na2HP0^ 0.4 gm./liter 
were added to 100 mis. of distilled water. A pH of 7.4 was obtained 
by titration with either IN HCL or IN NaOH. 
Of the above solution, 20 mis. were removed at each run of 
samples, to this 180 mis. of distilled water was added to bring the 
total volume to 200 mis. After termination of the experiments that 
day, the remaining amount of this solution was discarded. The 
remaining 80 mis. of PBS was stored at room temperature for further 
use. 
3. DPH Probe Preparation: 
One sealed ampule of DPH (D 1. ) was dispersed by pipette into 
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200 mis. of vigorously stirring PBS solution (D 2.). The obtained 
solution is clear and practically devoid of fluorescence. A fresh 
dispersion is made each day prior to the series of experiments. 
E. General Procedure: 
1. Preparation of Elscint Microviscosimeter: 
Twenty minutes prior to preparing the samples, the instrument's 
ON switch, located on the instrument panel, is depressed. The ON 
switch on the Auxiliary Power Supply, or START switch is also 
depressed for the Mercury Arc Lamp. 
2. Amniotic Fluid Preparation: 
Each sample of amniotic fluid is centrifuged at 1500 g's for 
10 minutes. Then, 0.5 mis. of clear supernatant is pipetted off. 
To this is added 2.0 mis. of the DPH dispersion (D 3. )• Inherent 
in the assessment of the FP value is a twenty percent dilution of 
amniotic fluid. The mixture thus prepared is shaken vigorously 
and incubated in a water bath at 37° C for twenty minutes, after 
which the samples are left at room temperature for fifteen minutes. 
3. Analysis: 
The sample to be analyzed is placed into a clean fluorescent 
quartz cuvette and placed in the sample holder of the instrument. 
The temperature is checked to be 25°C with the appropriate controls 
on the instrument. The cover for the sample is properly positioned 
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and the sample is analyzed according to Elscint Directions. 
This basic methodology was used on all the experimental 
investigations performed. 
II Experiments: 
A. Experiments were carried out to study the effect of the 
following manipulations on the FP value. 
1. Dilution of amniotic fluid utilizing: 
a. ILO 
b. PBS—phospate buffered saline 
2. Addition of maternal serum 
3. Addition of meconium utilizing: 
a. mature meconium from a term infant 
b. immature meconium from a preterm infant 
4. Freezing and thawing 
Inherent to the test is a 20% dilution of amniotic fluid (2 mis. of 
PBS dye solution). This is not considered a dilutional effect for 
it is necessary to calculate the FP. 
1. Effect of dilution on FP value utilizing PBS without dye 
and H^O without dye: 
Although a 20% dilution of amniotic fluid exists in order to 
calculate the FP value, further dilution of amniotic fluid by phosphate 
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buffered saline and distilled water was assessed to evaluate any 
change that this might incur on the original FP value. This dilu- 
tional change might be associated with technical error in preparation 
of the samples for analysis. 
Five amniotic fluid samples of varying FP values were 
examined. Two of the five samples were made from pooled amniotic 
fluid samples (Table 1). Each of the specimens was treated as per 
protocol in the methodology section. The results are tabulated in 
Tables 1, 2, and 3, while they are graphically displayed in Figure 1. 
In the initial experiment (Table 1) no significant change in FP 
value was demonstrated until a five fold dilutional level. There¬ 
after in the remaining experiments the earlier dilutions (less than 
five fold) were eliminated. 
Diluting the amniotic fluid matured or decreased the FP 
value. This maturation tendency was especially evident at a tenfold 
dilution (10%), except for sample #4 (Table 1) where the maturation 
occurs at a fivefold dilution (20%). Above these values, the FP 
remained stable at approximately the initial FP value. This 
decrease in FP value may cause false positive interpretation of 
maturity at critical decision levels if they were to occur. This 
possibility is, however, unlikely if one adheres to the selected 
proportion of amniotic fluid and dispersion solution required to 
carry out the analysis. 
2. Addition of Maternal Serum: 
Fetal and/or maternal blood may be an inadvertent contamination 
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of amniotic fluid during amniocentesis. Because of this potential 
problem, evaluation of the effect of varying amounts of serum con¬ 
tamination were made on the FP value. Serum was used because all 
samples are subjected to centrifugation for the determination of 
the FP value. The effect of different blood preparations was also 
assessed because of the possibility that samples may not have been 
immediately frozen and clotting may have occurred. 
Blood was collected from pregnant females, allowed to clot, 
or immediately frozen, or placed in heparin to avoid clotting. 
From these three sources, serum was removed after centrifugation. 
Two amniotic fluid samples were used to assess the results. Each 
specimen of amniotic fluid was analyzed according to the methodology 
section. 
The results are tabulated in Tables 4 and 5 with graphical 
display in Figure 2. 
Diluting amniotic fluid with even very small amounts of 
maternal serum tended to decrease (mature) the FP value in a similar 
fashion as did the PBS and H^O dilutions. This maturation tendency 
was especially evident at a tenfold dilution or at ten percent 
amniotic fluid. Above this level, the FP value remained stable at 
approximately the initial FP value. Thus, substitution of two percent 
serum to amniotic fluid-DPH dispersion mixture caused the FP value 
to fall significantly. 
Amniotic fluid increases rapidly to an average volume of 
50 mis. at 12 weeks gestation and 400 mis. at midpregnancy; it 
reaches a maximum of about a liter at 36 to 38 weeks gestation. 
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The volume then decreases as terra approaches, with variations of 
200-800 mis. At ten percent amniotic fluid, 0.40 mis. of serum 
is equivalent to contamination of 200 mis. of blood per liter of 
amniotic fluid. 
This important effect created by serum contamination, varies 
from the others in that contamination with blood is unavoidable 
in some cases, and unlike the previous experiment, cannot be 
attributed to technical error. This result, therefore, should be 
noted to avoid depending on the FP when gross amounts of contamination 
of amniotic fluid have occurred. 
Evaluation of non-maternal serum was assessed because other 
sources had utilized this source in determining the effect of con¬ 
tamination on amniotic fluid. This result is tabulated in Table 6 
and graphically displayed in Figure 2. 
Dilution or contamination of amniotic fluid with non-maternal 
serum tended to increase (immature) the FP value, in keeping with 
its effect in other studies on L/S ratio. 
This effect, though interesting is highly unlikely to occur. 
1* 
3. Addition of meconium utilizing term and preterm meconium: 
Meconium contamination of amniotic fluid is similar to serum 
contamination in that it is unavoidable when it occurs. To evaluate 
any change that this contamination might have on the original FP 
value, the following study was performed. 
Preterm and term meconium were added to term and preterm 
(mature and immature) amniotic fluid to assess the change or effect 

32 
on the FP value. 
Pooled samples of amniotic fluid were prepared to yield two 
types of amniotic fluid pools, immature (greater than 0.310) and 
mature (less than 0.310). Meconium was collected from two infants, 
one preterm at 32 weeks, and one term at 39 weeks. To facilitate 
handling, a dilutional scheme was developed whereby meconium was 
diluted with amniotic fluid at 1 gm./lO mis. of amniotic fluid. 
This led to two stock mixtures: 
1. immature meconium diluted with 2. mature meconium diluted 
immature amniotic fluid with mature amniotic fluid 
The two types of meconium, immature and mature, were therefore 
added to the similar types of amniotic fluid that would represent 
contamination, if it had occurred. The stock solutions of meconium 
were diluted with the same gestational type of amniotic fluid pool 
to be tested to avoid any changes in the FF value from the diluting 
medium. 
These results are tabulated in Table 7 and graphically 
displayed in Figure 3. 
From these data, which were repeated and yielded similar 
results, it seems apparent that: meconium, term or preterm, raises 
the FP value indicating immaturity; with addition of meconium, 
mature amniotic fluid tended to have a greater tendency to reach 
this immature state; and preterm meconium created less change than 
term meconium. 
Meconium contamination, be it of mature or immature amniotic 
fluid, tends to raise the FP to more immature values. This alteration 
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appears much greater in mature amniotic fluids. This may be due to 
greater sensitivity to contamination with meconium or perhaps this 
effect is due to a different lipid composition of the meconium. 
Because of this problem, perhaps gestational age should be taken 
into account if one is analyzing fluid that is contaminated with 
meconium, for false positives, indicating immaturity, are possible. 
4. Freezing and Thawing: 
Samples from various patients and from pooled samples were 
frozen and thawed and refrozen or left at room temperature for 
varying lengths of time to assess any change in the FP value. 
These results are tabulated in Table 8. 
It is clear from the data, that caution should be taken with 
freezing and thawing of samples; changes of up to +.020 and -.026 
were observed without any predictable trend. However, it should 
be noted that not freezing a particular sample, or forgetting to 
freeze a sample for up to three days does not alter the FP value 
significantly. 
II Experiments: 
B. Analysis of Data Collected on Patients: 
For this study, attempts were made to ascertain FP in 
different disease states, to compare FP with the L/S ratio, 




Samples included amniotic fluid from patients with various 
disease states as well as with normal pregnancies as follows: 
samples from 10 patients with normal pregnancies between 34-41 
weeks gestation; 9 samples from Rh patients between 21-39.5 weeks 
gestation; a 39.5 week sample from one patient with cardiac disease; 
samples from 17 diabetic patients between 35-40 weeks; 9 samples 
from eclamptic patients 31-41 weeks; two samples from PROM 37-39 
weeks; four samples of postmaturity all greater than 40 weeks; six 
samples of hydramnios at 33-40 weeks; and 5 IUGR samples. 
Gestational age was assessed from obstetrical data, including 
IMP, estimated uterine size, and ultrasound with BPD. Amniotic 
fluid was obtained by trans-abdominal amniocentesis. All samples 
were labelled with date of delivery and ultimate outcome of infant, 
retrieved from records retrospectively. L/S ratios and FP values 
were made on each sample of amniotic fluid. 
2. Method: 
All samples were centrifuged and the FP value measured as 
per protocol in the methodology section. Permission was obtained 
for utilization of two "Elscint Fetal Lung Maturity Analyzers." 
Samples were analyzed with both instruments and for L/S ratios if 
enough fluid was obtained. The results for the two instruments 
are labelled as FP( 1) for the analyzer at YNHH and FP(2) for the 
analyzer located in N.Y.C. Samples analyzed in N.Y.C. were frozen 
immediately at YNHH at -2°C after centrifugation and taken to the 
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area on dry ice. These samples were then analyzed identically, 
in accordance with protocol. 
An FP( 1) value of .310 is the upper limit threshold above 
which RDS may occur while an FP(2 ) value of .336 is the upper limit 
threshold of the N.Y.C. instrument. A value less than or equal 
to .310 and .336 for FP(l) and FP(2) respectively have therefore, 
been claimed to indicate lung maturity. 
3. Results: 
A. Histogram: 
A histogram (Figure 4) was created to show the distribution 
of patients for each particular L/S ratio and to emphasize the 
number of patients (frequency) actually used in evaluating FP values 
for particular L/S ratios. 
B. ^ FP values and increasing gestational age: 
Table A shows tabulated data of FP values and L/S ratio for 
increasing gestational age. This gives easy evidence to all results 
and to corresponding L/S ratios. The L/S ratio shows the usual 
trend of increasing maturity with advancing gestational age, with 
some scatter noted for particular disease states. This similar 
trend of increasing maturity is noted for the FP value. IUGR and 
Eclampsia, tend to have higher L/S ratios at an earlier gestational 
age than other diseases at comparable gestational ages. This is 
evident at approximately 34 weeks. This same trend was noted in 
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Class A and B diabetics when compared to Class C and D diabetics. 
L/S ratios for the former at approximately 38 weeks were much higher. 
Class A diabetics, in fact at 39 weeks had higher L/S ratios than 
other diseases at comparable gestational age. The L/S ratio 
surprisingly seemed to be especially low for samples with hydramnios 
at 40 weeks if compared to other disease states. 
B»2 Correlation of FP and L/S to ultimate fetal outcome: 
Three patients whose infants developed RDS, #6, 13 and 48, 
are shown in Table A. Their gestational ages are 31, 34, and 40 
weeks respectively. At forty weeks gestation, development of RDS 
is extremely rare, but #48 was noted to have mild RDS as diagnosed 
in Poughkeepsie, New York. FP(1) and the L/S ratio predicted #6, 
but insufficient fluid was obtained to calculate FP(2). The L/S 
ratio and FP(1) failed to predict the outcome in #13 while FP(2) 
did predict immaturity. Bot FP values failed to predict immaturity 
in #34 while the L/S ratio estimated this result. 
B.^ Evaluation of false positives and false negatives were 
assessed to compare FP results to the L/S ratio. 
The false positive rate was defined as all those samples 
with an L/S greater than or equal to two with an immature FP value 
(greater than .310 (FP(l) and .330 (FP(2)). The total false positive 
rate for the FP was 10.9# for FP(1) and 24.2# for FP(2). To evaluate 
ultimate outcome of all false positive infants, all those infants 
with false positive values who were delivered within three days of 
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the test were evaluated. The three day period was picked to avoid 
maturation that would have occurred if longer periods of time were 
used. A total of five false positive infants were found within 
that time period. One did develop RDS #13, not predicted by the 
L/S ratio while four, three from FP(2) and one from FP(1) did not, 
even though the FP value predicted that they should. 
The total false negative rates were evaluated. This rate 
is defined as all those infants with immature L/S ratios and FP 
values of less than or equal to .310 (FP(l)) and .336 (FP(2)). The 
false negative rate was assessed to be 21.8% and 17.74% for FP(1) 
and FP(2) respectively. Again to evaluate infant outcome, all 
false negative infants delivered within three days of the test 
were evaluated. In this case, again one #48 developed RDS, while 
four, #'s 11, 20, 29, and 49 did not. These four were therefore, 
not false negatives since the L/S erred and these infants did not 
develop RDS. This consideration was taken when calculating the 
false negative rate. The results were estimated as a false negative 
rate of 14.5% and 11.3% for FP(1) and FP(2) respectively, a change 
of 7.3% and 6.4% respectively. 
The true positive rates for FP(1) and FP(2) were calculated 
as 40% and 32.25% respectively while the true negative rate, taking 
again into account the four new patients (#'s 11, 20, 29 and 49), 
was 34.5% and 32.2% respectively. 
All values that did not correlate with the L/S ratio were 
totaled. These were 25.4% for FP( 1) and 35.5% for FP(2). 
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Table B was analyzed for false positives and false negatives 
to evaluate any correlation to disease states. The false positive 
rate was especially greater in diseases such as IUGR and Class A 
diabetics, while the false negative rate tended to cluster in 
diseases such as Class C diabetics and hydramnios. 
B. . Predictive values 
4 
Disregarding RDS or infant outcome, the probabilities for 
L/S ratios at a given FP were assessed. This was calculated to 
establish the trend of the instrument with regards to L/S ratio. 
The probability of a mature L/S ratio given a mature FP value 
(less than or equal to .310 or .330) was 64.7$ and 64.5$ for FP(1) 
and FP(2) respectively. The probability of an immature L/S ratio 
given a mature FP value was 35.3$, FP(1) and 35.5$, FP(2). The 
probability of a mature L/S ratio given an immature FP value 
(greater than .310 and .336) was 28.5$, FP(1) and 48.3$, FP(2). 
The probability of an immature L/S ratio given an immature FP 
value was 71.4$, FP(1), and 51.6$, FP(2). 
C. FP values correlated with L/S and gestational age 
The average FP values with standard deviations were tabulated 
for an L/S ratio greater than or equal to two and for an L/S ratio 
less than two, to demonstrate the trend of the instrument. When 
the mean FP values are compared to the L/S ratio, Figures 4A and 4B, 
they show good association. FP(1) and FP(2) differ in their slope 
of increasing maturity. FP(l), Figure 4A, shows a rapid and early 
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increase in maturity at an L/S ratio of 1.1-1.9 while FP(2) shows 
a more gradual increase in maturity that is evident at an L/S ratio 
of 2.9-3-7 (Figure 4B). Both values show a wide standard deviation 
(S.D. ) at an L/S of 2.9-3-7 and especially at an L/S greater than 
5.6 for FP( 2 ). 
Because maturity was reached at different L/S ratios for 
FP(1) and FP(2), a correlation with gestational age was done. FP 
values compared to gestational age, Figure 40, show that average 
maturity was not reached for FP(1) until 34-35 weeks, and 38-39 
weeks for FP(2). In comparison, when the average L/S was tabulated, 
maturity was noted at a mean gestational age of 39.2 weeks. Both 
FP values, therefore, matured earlier than the L/S ratio. They, 
nevertheless, show a gradual decline with increasing L/S ratio and 
advancing gestational age, indicating maturity. 
D.^ Maternal Diseases: 
To evaluate any underlying trend that might be altering the 
FP value, average values for maternal diseases were plotted at 
immature and at mature L/S ratios. The diseases plotted against 
mean FP values are in Figure 5A, at an L/S greater than or equal 
to two, and Figure 5B, at an L/S less than two. 
The mean FP values at a mature L/S were also mature for all 
evaluated disease states in FP(l). Nevertheless, cesarean section, 
pre-eclampsia and post-maturity tended to have lower mean FP values, 
indicating increased maturity, when compared to those samples of 
IUGR, class A diabetics and hydramnios. To evaluate this discrepancy, 
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mean gestational ages for each of these disease states at an L/S 
of greater than two was analyzed from the data in Table B. These 
ages were, 37.5, 38.6, and 38.5 for IUGR, class A and hydramnios 
compared to the mean gestational ages of 39.16, 38.16 and 40.8 for 
cesarean section, eclampsia and post-maturity respectively. FP(2) 
at an L/S greater than or equal to two, tended to have mean values 
that indicated maturity for cesarean section, eclampsia, and post- 
maturity. Again, a similar trend was noted as in FP(1) where 
disease states such as IUGR and class A diabetics tended to have 
higher mean FP values. In fact, the mean values of these two states 
were in the immature FP range (greater than .336). 
Evaluation of mean FP(1) values at an L/S less than two 
(Figure 5B) shows immature values for Rh disease and eclampsia yet, 
class C and D diabetics and hydramnios show mean values in the 
mature range. Mean FP(2) values show a similar trend, with class D 
diabetics and hydramnios samples at a mean maturity range yet at an 
L/S of less than two. 
D.^ Evaluation of Maturation Trend: 
To evaluate the trend of maturity, eclampsia was analyzed. 
The mean value for eclampsia at an L/S of less than two, Figure 5B, 
was .312 for FP(1) and .340 for FP(2). This mean value changed at 
an L/S greater than two to .270 for FP(1) and .305 for FP(2), 
Figure 5A. The maturation change confirms correlation with the 
L/S ratio. Other diseases were analyzed in a similar fashion. 
Surprisingly, in comparison the mean values for hydramnios at an 
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L/S less than two were .280 for FP(1) and .300 for FP(2), yet 
changed very little to .290 and .310 for FP(l) and FP(2) respectively, 
at an L/S ratio of greater than two. This lack of maturation 
usually associated with a maturing L/S ratio is also seen in 
diabetic samples, plotted in Figure 6A. There is also little 
change in the mean FP values for all diabetics at an L/S ratio 
of greater than or less than two. These diabetic and hydramnios 
samples were therefore, compared to gestational age, Figure 6B, 
and Table B. It is worth noting, that for hydramnios, the patients' 
mean gestational ages were the same for both mature and immature 
L/S ratios (38 weeks). For the diabetic sample, in comparison, 
the mean gestational age did show a change from 35-38 weeks with 




Since surfactant lowers surface tension, which is a function 
of microviscosity, it seems likely that an instrument that could 
measure this function could be of use in evaluating fetal lung 
maturation and therefore, RDS. 
Our experimental data showed fairly good correlation of the 
FP value with the L/S ratio. The FP tends to mature earlier than 
the L/S ratio, showing better association to known fetal maturity 
at approximately thirty-five weeks. 
Experimental contamination of amniotic fluid samples with 
dilutional factors tended to alter the FP value and caused false 
maturation to occur. This dilutional effect is not in keeping 
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with current published data where no change was noted up to 
a ten fold dilution. 
Experimental contamination with term or preterm meconium 
caused falsely elevated (immature) FP values. This effect was 
especially pronounced in fluids with mature FP values, perhaps 
indicating a particular sensitivity of this fluid to alteration. 
Term meconium rather than preterm meconium tended to increase this 
effect, perhaps secondary to varying amounts of lipids or changes 
in its composition. 
Experimental contamination with blood is of interest because 
alteration of the FP was dependent on the type of serum used, but 
maternal blood matured FP. 
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In summary, our study shows that false positive results 
secondary to meconium contamination and false negative results 
secondary to blood and dilutional changes may develop in the 
analysis of the FP value. This tendency must be carefully 
evaluated in the event of unavoidable contamination. Dilutional 
error are, however, unlikely to occur and therefore does not 
require such caution unless extremely poor technique is applied. 
Almost all amniotic fluid measurements including the L/S ratio 
are affected by blood and meconium. Nevertheless, reliance on the 
FP value in samples that are contaminated with greater than 20% 
serum or as little as 0.5 mg/ml of meconium should be cautiously 
appraised at present. 
The disease states of diabetes and hydramnios tended to 
alter the FP value. The stable maturation means reflected in 
these two diseases can only be explained in hydramnios. This 
effect may have been due to the dilutional change of the amniotic 
fluid that may have falsely lowered the L/S ratio without a 
similar effect on the FP, or perhaps there was greater correlation 
of FP values with gestational age. Mean gestational age, however, 
did change for diabetic samples while the mean FP values remained 
constant. There is no explanation for this result. One may 
speculate that perhaps the microviscosity of the amniotic fluid 
was altered in the diabetic state. 
58 
Gluck and coworkers notedtwo mean maturation slopes for 
different disease states. L/S ratios in classes D, E, and F 
matured earlier at 32-33 weeks while, classes A, D, and C diabetics 
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tended to mature late at 37-40 weeks. Our L/S ratios did not 
demonstrate this trend. Interestingly, the mean FP value does 
show this trend, not correlating well with the L/S ratio in this 
disease, and demonstrates low (mature) values for classes D and C 
at an L/S of less than two, and high (immature) values for classes 
A and B at an L/S greater than two. Thus, the FP correlates with 
Gluck's data. 
Although fairly good correlation with the L/S was achieved, 
the false positive rate of 10-24# for FP(1) and FP(2) and the 
false negative rate of 14.5# and 11.3# for FP(2) and FP(l) are 
disturbing. Utilization of this instrument without or instead 
of the L/S ratio would therefore allow the delivery of 11-14# of 
infants who would not be demonstrated as mature by L/S standards. 
Whether these infants would in fact develop RDS is an unanswerable 
question at present. Similarly, 10-24# of infants considered 
mature by the L/S ratio would be considered immature by FP standards 
and would not be delivered. Their maturity, or the effect of 
delayed delivery also cannot be assessed. 
Time and much evaluation will be our only tools to answer 
these questions. At present, our analysis is not conclusive. 
Correlation with gestational age and L/S is good save for two 
disease states. Nevertheless, further evaluation in a setting 
where the results can be analyzed in terms of infant outcome (RDS) 
is needed to evaluate not only efficiency but worth. 
The procedure for measuring FP with the Elscint instrument 
is simple and highly reproducible but, further evaluation of the 
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instrument is needed as well as more stringent and safer quality 
controls. Adequate standardization levels were not available 
during this study which created uncertainties with regards to 
daily mechanical functions. 
Given that the instrument measures the microviscosity of 
phospholipid liposomes, sonication of the amniotic fluid samples 




Epidemiological data have shown RDS to be the leading 
cause of neonatal deaths. The L/S ratio is at present the leading 
laboratory method utilized for prediction of lung maturation. The 
Elscint Fetal Lung Maturity Analyzer appears to have potential in 
its prediction of lung maturity. Therefore, its potential useful¬ 
ness for prediction of RDS or lung maturity has been assessed. 
Alteration of the FP value by contamination and changes imposed 
by certain high-risk patients, may lead to problems in its overall 
use by clinicians. At present, further evaluation is needed to 
establish its efficiency in the prediction of lung maturation, 
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Table 1 Effect of Dilution on FP Value 
ution of Amniotic Fluid , Sample 3, Utilizing Distilled H 0 
2 
Sample H 0 in o A.F. in FP Change fr 
#'s mis. mis. Value initial ' 
1 0.0 0.50 . 317 
2 0.05 0.45 . 315 -.002 
3 0.10 0.40 .318 + .001 
4 0.20 0.30 .320 + .003 
5 0.30 0.20 .318 + .001 
6 0.40 0.10 . 315 - .002 
7 0.45 0.05 . 302 -.015 
8 0.50 0.00 .275 - .042 
DPH dispersion is added (2 mis.) to all samples to be analyzed 
A.F.= amniotic fluid ; H^O = distilled water ; FP = fluorescent 
polarization 
Dilution of Amniotic Fluid, Sample 4, Utilizing Phosphate Buffered Saline (PBS): 
Sample H O in A.F. in FP Change fri 
#’s mis. mis . Value initial j 
1 0.0 0.50 . 332 
2 0.05 0.45 .331 -.001 
3 0.10 0.40 .331 -.001 
4 0.15 0.35 .326 -.006 
5 0.20 0.30 .323 - .009 
6 0.25 0.25 .323 -.009 
7 0.30 0.20 .315 -.017 
8 0.40 0.10 .306 - .026 
9 0.45 0.05 .293 -.039 
10 0.50 0.00 .277 -.055 
* 
DPH dispersion (2 mis. ) is added to all samples 
A.F.=amniotic fluid ; FP=fluorescent polarization 
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Table 2 Effect of Dilution on FP Value 











1 0.00 0.50 .352 
2 0.40 0.10 . 346 -.006 
3 0.45 0.05 .332 -.020 
4 0.475 0.025 .302 -.050 
5 0.50 0.00 .267 -.085 
DPH dispersion ( 2 mis.) is added to all samples 
A.F.= amniotic fluid ; H20= distilled water; FP = fluorescent polarization 











1 0.00 0.50 .308 
2 0.40 0.10 .303 - .005 
3 0.45 0.05 .288 -.020 
4 0.475 0.025 .266 -.042 
5 0.50 0.00 .255 -.053 
DPH dispersion ( 2 mis.) is added to all samples 
A.F. = amniotic fluid 
FP = fluorescent polarization 
PBS = phosphate buffered saline 

Table 3 Effect of Dilution on FP Value 
51 
ution of Amniotic Fluid , Sample A, Utilizing 1) distilled H20 
2) PBS-phosphate bu 
lied H20 
Sample H9O in A.F. in FP Change from 
#' s mis . mis . Value initial FP 
1 0.00 0.50 .274 
2 0.10 0.40 .274 .000 
3 0.20 0.30 .280 + .006 
4 0.40 0.10 .268 -.006 
5 0.45 0.05 .255 -.019 
6 0.475 0.025 .242 - .022 
7 0.50 0.00 .240 -.024 
DPH dispersion( 2 mis.) is added to all samples 
A.F.= amniotic fluid; H 0 = distilled water; FP= fluorescent polarization 
Phosphate Buffered Saline: 
Sample PBS in A.F. in FP Change from 
#1 s mis. mis . Value initial FP 
1 0.00 0.50 .274 
2 0.10 0.40 .276 + .002 
3 0.20 0.30 .280 + .006 
4 0.40 0.10 .268 - .006 
5 0.45 0.05 .257 - .017 
6 0.475 0.025 .243 - .021 
7 0.50 0.00 .240 -.024 
* 

















Effect of Dilution on FP Value, Utilizing Distilled 
Water and Phosphate Buffered Saline 
1 po4 
2 H20 
3 H20 Pool 
4 P04 pool 
A P04 & K O 
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Table 4 Effect of Maternal Serum on FP Value 
A. Clotted Blood ( Utilizing Serum): 
Sample Serum in A.F. in FP Change from 
#'s mis. mis. Value initial FP 
1 0.00 0.50 . 310 
2 0.01 0.49 .293 - .017 
3 0.05 0.45 .288 -.032 
4 0.10 0.40 .283 -.027 
5 0.50 0.00 .261 -.049 
Heparinized Blood ( Utilizing Serum): 
Sample Serum in A.F. in FP Change from 
#'s mis. mis. Value initial FP 
1 0.00 0.50 .310 
2 0.01 0.49 .291 -.019 
3 0.05 0.45 .286 -.024 
4 0.10 0.40 .285 -.025 
5 0.50 0.00 .258 -.054 
Immediately Frozen ( Utilizing Serum): 
Sample Serum in A.F. in FP Change from 
#'s mis. mis . Value initial FP 
1 0.00 0.50 . 310 
2 0.01 0.49 .287 -.023 
3 0.05 0.45 .280 -.030 
4 0.10 0.40 .281 -.029 
5 0.50 0.00 .254 -.056 
* 
DPH dispersion (2mls .) is added to all samples 
A.F.= amniotic fluid 
FP = fluorescent polarization 
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Table 5 Effect of Maternal Serum on FP Value 
D. Immediately Frozen ( Utilizing Serum): 
Sample Serum in A.F. in FP Change from 
#'s mis . mis. Value Initial FP 
1 0.00 0.50 .311 
2 0.01 0.49 .285 -.026 
3 0.025 0.475 .285 -.026 
4 0.05 0.45 .285 -.026 
5 0.10 0.40 .285 - .026 
6 0.15 0.35 .289 - .022 
7 0.20 0.30 .295 -.016 
8 0.25 0.25 .280 -.031 
9 0.40 0.10 .270 -.041 
10 0.50 0.00 .250 -.061 
*DFH dispersion ( 2 mis.) is added to all samples 
A.F. = amniotic fluid 
FP = fluorescent polarization 
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Table 6 Effect of Non-Maternal Serum on the FP Value 
E. Immediately Frozen Non-Maternal Serum: 
Sample Serum in A.F„ in FP Change from 
#'s mis . mis. Value initial FP 
1 0.00 0.50 .310 
2 0.01 0.49 .312 + .002 
3 0.05 0.45 . 318 + .008 
4 0.10 0.40 .320 + .010 
5 0.40 0.10 .332 + .022 
6 0.50 0.00 .347 + .037 
DPH disper sion ( 2 mis.) is added to all samples 
A.F.= amniotic fluid 
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Effect on FP Value With Addition of Maternal and Non-Maternal 
Serum. 

Table 1 Effect of addition of term and preterm meconium on the FP value 















1 0.00 0.50 0.00 . 343 
2 0.01 0.49 2.00 .352 + .009 
3 0.025 0.475 5.00 .351 + .008 
4 0.05 0.45 10.00 .350 + .007 
5 0.10 0.40 20.00 . 348 + .005 
6 0.25 0.25 50.00 — — 
-= no ' data was obtained from instrument 















1 0.00 0.50 CO. 00 .272 
2 0.01 0.49 02.00 .285 + .013 
3 0.025 0.475 05.00 .290 + .018 
4 0.05 0.45 10.00 . 300 + .028 
5 0.10 0.40 20.00 .322 + .050 
6 0.25 0.25 50.00 _ _ 
- = no data obtained from instrument 
* 








Figure 3 Effect on FP Value With Addition of Preterm and Term 
Meconium 
MecOnium mg/ml 




Table 8 Effect of Temperature and Time on the FP Value 
IV Freezing and Thawing:* (A) 
Sample Initial Time New Change Disease of 
Frozen in 
# FP Days FP Pa tien t 
1 .345 99 . 350 + .005 Rh Disease 
2 . 342 97 . 362 + .020 Rh Disease 
3 .304 73 . 304 .000 PROM 
4 .334 57 .320 -.014 Diabetic 
5 .314 51 .306 - .008 Pre-eclampsia 
6 .330 36 .342 + .012 Rh Disease 
7 .2 34 8 .234 .000 Hydramnios 
8 .308 8 .304 - .004 Diabetic 
9 .308 21 .282 -.026 Norma 1 
10 . 315 14 .315 .000 Hydramnios 
11 .292 10 . 303 + .011 Diabetic 
(B) Effect of Time 
Sample Initial 24 Change 48 Change 72 Change 
# FP Hours Hours Hours 
1 . 317 .317 .000 .315 -.002 .316 -.001 
2 .234 .234 .000 .234 .000 .235 + .001 
3 . 304 . 310 + .006 .295 -.009 .310 + .006 
4 .272 .270 -.002 .274 + .002 .272 .000 
5 .314 . 315 + .001 .314 .000 .315 + .001 
6 .303 .304 + .001 .309 + .006 . 304 + .001 
Average days frozen = 43 
Average change = .009 - .008 S.D. 
* DPH dispersion was added in the constant amount of 2 mis. to all 
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FP (2 ) 
value 




21 0.5 .36 7 . 390 + .02 3 Rh Dis. 
25 0.5 . 351 .392 + .041 Rh Dis. 
26 1.0 .342 . 383 + .041 Rh Dis. 8/9 62 
28 1.2 .298 .334 + .036 Rh Dis. 
30 0.5 .301 . 339 + .038 Rh Dis. 
31 0.7 .316 Pre-eclam. 1/3 0 
31 1.3 . 340 .373 + .033 Pre-eclam. 8/6 20 
32 0.2 . 369 Rh Dis. 
33 0.5 . 315 .343 + .028 Hydram. 5/8 8 
34 0.5 . 322 .365 + .043 Pre-eclam. 4/6 4 
34 1.5 .280 . 320 + .040 Rh Dis. 6/7 2 
34 2.0 . 324 .366 + .042 IUGR 9/9 1 
34 2.1 .225 .341 + .116 Norm. C/S 7/9 0 
34.5 1.6 .320 .355 + .035 Rh Dis. 8/9 14 
34.5 2.9 .304 . 334 + .030 Pre-eclam. 
35 1.6 .321 .354 + .033 Class A 7/8 6 
35 1.6 . 326 .355 + .029 Class B 7/9 7 
35 1.6 .285 .316 + .031 Class C 8/8 5 
36 0.5 .312 .375 + .06 3 Class C 
36 1.4 .283 . 312 + .029 Class D 1/7 2 
36 2.4 .312 .347 + .035 IUGR 9/9 11 
37 0.3 . 342 . 378 + .036 PROM 8/8 35 
37 1.1 .294 .345 + .051 Class C 
37 1.9 .276 .300 + .024 Pre-eclam. 6/8 6 
37 3.4 .314 .351 + .037 Class A 8/9 9 
37.5 1.6 .328 .347 + .019 Pre-eclam. 
37.5 3.4 . 339 Cardiac 9/9 3 
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Table A continued 
Tabulation of all data 
Sample Gest. Age L/S FP(1) FP(2) Change Disease Apgar # days 
#'s in weeks ratio value value # post term 
28 38 1.1 . 304 .329 + .025 Class D 8/9 10 
29 38 1.2 . 311 . 330 + .019 Pre-eclam. 5/8 0 
30 38 1.8 .318 .358 + .040 Class C 9/9 7 
31 38 1.9 .293 .322 + .029 Class C 8/9 10 
32 38 2.0 .268 .284 + .016 Hydram. 8/9 1 
33 38 2.3 . 364 Norm. C/S 
34 38 2.9 . 309 .351 + .042 Class A 8/9 6 
35 38 4.5 .345 Class B 9/9 0 
36 38 8.3 .319 Class A 
37 39 1.4 .283 .320 + .037 Hydram. 7/8 6 
38 39 2.1 .304 . 337 + .033 PROM 9/9 1 
39 39 2.7 .319 .325 + .006 IUGR 9/9 10 
40 39 3.2 .308 .350 + .042 Class A 8/8 6 
41 39 2.7 .319 .336 + .017 Hydram. 7/8 6 
42 39 3.3 .290 .338 + .048 IUGR 8/8 4 
43 39 5.0 .286 .332 + .046 IUGR 9/9 10 
44 39 5.5 .263 Norm. C/S 
45 39 7.7 .282 .339 + .035 Pre-eclam. 7/9 11 
46 39.5 2.4 .274 .332 + .058 Class C 9/9 3 
47 39.5 5.9 .201 Rh Dis. 9/9 0 
48 40 1.8 .284 .302 + .018 Hydram. 7/8 
■k 
6 
49 40 1.8 .234 .257 + .023 Hydram. 9/9 0 
50 40 2.0 .291 .315 + .024 Norm. C/S 4/9 4 
51 40 2.0 .279 .319 + .040 Norm. C/S 9/10 0 
52 40 2.4 .255 .331 + .076 Norm. C/S 9/9 0 
53 40 2.9 .251 .321 + .070 Norm. C/S 9/9 3 

Table A continued 
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54 40 3.1 
55 40 3.6 . 197 
56 40 3.9 .268 
57 40 4.5 .292 
58 40 4.8 .217 
59 40 5.7 . 321 
60 41 4.2 .2 32 
61 41 4.8 .206 
62 41 6.8 .259 
63 42/5 4.7 .270 
Gest. Age= gestational age in weeks 
FP = fluorescent polarization 
* = infant developed RDS 
Change Disease Apgar # days 
# post term 
Norm. C/S 8/9 3 
i .023 Postmatur. 9/9 1 
+ .06 5 Pos tmatur. 9/9 0 
+ .046 Class A 9/9 6 
+ .035 Norm. C/S 
+ .033 Class A 7/8 6 
+ .025 Pre-eclam. 9/9 1 
+ .013 Postmatur. 9/9 2 
+ .035 Norm. C/S 9/9 0 














Table B Tabulation of data according to disease states of patients, in 









FP (2 ) 
value 
Change Apgar days post test 
32 0.2 .369 
21 0.5 .367 .390 + .023 
25 0.5 .351 .392 + .041 
25 0.5 .373 
30 0.5 .301 .339 + .038 
26 1.0 .342 .383 + .041 8/9 62 
28 1.2 .298 .334 + .036 
34 1.5 .280 .320 + .040 6/7 2 
34.5 1.6 . 320 .335 + .035 8/9 14 
39.5 5.9 .201 9/9 0 
Mean: at L/S > 2; at L/S < 2 
Gest. Age: 39. 5; 28.4 
FP(1): > .322, false (-) 3/7 
FP (2): .201 3 .361, false (-) 2/9 No false (+) 








FP (2 ) 
value 
Change Apgar days post test 
40 2.0 .279 . 319 + .040 9/10 2 
40 2.0 .291 .315 + .024 4/9 4 
34 2.1 .225 .341 + .116 7/9 o' 
38 2.3 . 364 
40 2.9 .251 . 321 + .070 9/9 3 
40 3.1 .298 8/9 3 
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Table B Tabulation of data according to disease states of patients, in 
order of increasing L/S ratio 








FP (2 ) 
value 
Change Apgar days post test 
39 5 .5 .263 
41 6 .8 .259 .294 + .035 9/9 0 
40 2 .4 .255 .331 + .076 9/9 0 
40 4 .8 .217 .252 + .035 
Mean: at L/S > 2 ; at L/S < 2 
Gest age: 39.2 5 00, L/S false (+) 1/10 with infant developing RDS 
FP(1): .253 5 000, false (+) 1/7 with infant developing RDS 









FP (2 ) 
value 
Change Apgar days post 
34 0.5 .322 .365 + .043 4/6 6 
31 0.7 .316 1/3 0 
38 1.2 .311 . 330 + .024 6/8 6 
31 1.3 .340 .373 + .033 6/8 20 
37.5 1.6 . 328 .347 + .019 
37 1.9 .276 . 300 + .024 6/8 6 
34.5 2.9 . 304 .334 + .030 
41 4.2 .232 .257 + .025 9/9 1 
39 7.7 .282 . 336 + .054 7/9 11 
Mean: at L/S > 2 ; at L/S < 2 
Gest. Age: 38.2 ; 34.75 
FP(1): .272 ; -315 , false (-) 1/6, No false (+) 
FP(2): .309 ; .343 , false (-) 2/5, No false (+) 
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Table B Tabulations of data according to disease states of patients, in order 





L/S FP (1) 
ratio value 
FP (2 ) 
value 
Change Apgar days post test 
37.5 3.4 . 339 9/9 3 





L/S FP (1) 
ratio value 
FP (2 ) 
value 
Change Apgar days pos t test 
37 0.3 .342 .378 + .036 8/8 35 
39 2.1 .304 .336 + .032 9/9 1 
Mean: at L/S > 2 ; at L/S < 2 
Gest. Age: 39 ; 37 
FP(1): .304 ; .342, No false (+) or (-) 





L/S FP (1) 
ratio value 
FP (2 ) 
value 
Change Apgar days pos t test 
34 2.0 .324 .366 + .042 9/9 1 
36 2.4 .312 .347 + .035 9/9 11 
39 2.7 .319 .325 + .006 9/9 10 
39 3.3 .290 .338 + .048 8/8 4 
39 5.0 .286 .332 + .046 8/9 1 
Mean: at L/S > 2 
Gest. Age: 37.4 
FP(1) .306 , false (+) 3/5 
FP(2) .341 , false (+) 3/5 
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Table B Tabulation of data according to disease states of patients, in 
order of increasing L/S ratio 








FP (2 ) 
value 
Change Apgar days post 
35 1.6 . 321 .354 + .033 7/8 6 
38 2.9 .309 .351 + .042 8/9 6 
39 3.2 .308 .350 + .042 8/8 1 
37 3.4 .314 .351 + .037 8/9 9 
40 4.5 .2 92 .338 + .046 9/9 6 
40 5.7 . 321 .354 + .033 6/8 2 
38 8.3 .319 
Mean: at L/S > 2 ; at L/S < 2 
Gest. Age: 38.6 ; 35 
FP(1): .308 ; .321, false (+) 2/5, No false (-) 
FP (2 ) : .343 ; .354, false (+) 5/6, No false (-) 








FP (2 ) 
value 
Change Apgar days post 
35 1.6 . 326 . 355 + .029 7/9 6 
38 4.5 .345 9/9 0 
FP(2) false ( 








FP (2 ) 
value 
Change Apgar days post 
36 0.5 . 312 . 375 + .06 3 
37 1.1 .294 . 345 + .051 
35 1.6 .285 .316 + .031 8/8 5 
38 1.8 . 318 .358 + .040 9/9 7 
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Table B Tabulation of data according to disease states of patients, in 
order of increasing L/S ratio 
Diabe tes: continued Class "C" 
Gestational 
Age L/S FP (1) FP (2 ) Change Apgar days post test 
in weeks ratio va lue value 
38 1.9 .293 .322 + .004 8/9 10 
39.5 2.4 .274 .332 + .058 9/9 3 
Mean: at L/S >2 ; at L/S < 2 
Gest. Age: 39. 5 ; 36.8 
FP(1): .274 ; .300, false (-) 3/5, No false (O 
FP(2) : .332 ; . 343, false (-) 2/5, No false (O 










Change Apgar days post 
38 1.1 .304 . 329 + .025 8/9 10 
36 1.4 .283 .312 + .029 1/7 2 
Mean: at L/S < 2 
Gestational age: 37 
FP(1): .293, false (-) 2/2, No development of RDS 









FP (2 ) 
va lue 
Change Apgar days post 
40 3.6 . 197 .220 + .023 9/9 1 
40 3.9 .268 .333 + .06 5 9/9 0 
42.5 4.7 .270 .376 + .106 9/9 8 
41 4.8 .206 .219 + .013 9/9 2 
Mean: at L/S > 2 
Gest. age: 40.8 
FP (1): .235 while FP(2) .287 with false (+) 1/4 
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Table B Tabulation of data according to disease states of patients, in 









FP (2 ) 
value 
Change Apgar days post 
33 0.5 . 315 . 343 + .028 5/8 8 
39 1.4 .283 .320 + .037 7/8 6 
40 1.8 .284 .302 + .018 7/8 6 ' 
40 1.8 .2 34 .257 + .023 9/9 0 
38 2.0 .268 .284 + .016 8/9 1 
39 2.7 . 319 .336 + .017 9/9 9 
Mean: at L/S >2 ; at L/S < 2 
Gest. age: 38.5 > 38 
FP(1): .293 5 .279, false (+) 3/4, one (*) developed RDS 
FP (2) : .310 5 . 305, false (+) 3/4, one (*) developed RDS 
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Figure FP Values at increasing L/S ratios 
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Figure i4C Average FP Values at increasing gestational 























Figure 5A > 2 
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Figure 5B L/c, < 2 Average FP Value of Various Disease 
States, at an L/S ratio < 2 
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